Codexis, Inc (NASDAQ: CDXS) and Casdin Capital announce the launch of SynBio Innovation Accelerator. The goal of this accelerator is to help to raise early-stage companies financially and by providing unique product development capabilities in the field of synthetic and industrial biotechnology. Casdin Capital pledge to invest $50 million into companies tied to the industry and the SynBio Innovation Accelerator.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
At this announcement John Nicols, President and CEO of Codexis said that they are at a tipping point for Synthetic Biology, as the genomic revolution enhanced our ability to read and translate the blueprint of life, and in the process enabled a second and equally powerful SynBio revolution. Today we have a remarkable ability to not just read DNA but write and engineer transformative biologic products. He further commented that the Codexis’ 20-year history told us that it takes more than money to deliver distinguished products to the market. He is optimistic that the Codexis’s proven protein engineering technology and Casdin’sCapital’s financial resources will be a great combination.
The managing partner of Casdin CapitalEli Casdin said that this is not their first collaboration and we have similar initiatives in the bio-production industry with other companies such as with BioLife Solutions. He further said that his model has previously enhanced innovation and he is fully confident that it will have a huge impact in the synthetic biology space and accelerate the growth of this emerging technology field.
Codexis and Casdin are jointly making a $1.75 million investment under SynBio Innovation Accelerator and launched a computational protein design company, Arzeda. Also, both companies will collaborate on areas of synergy and mutual advantage. Arzeda core focus will be on computational approaches to designing novel enzyme functionality. The Company will use Codexis existing proprietary informatics tools and its highly efficient screening and optimization workflows.
